Cipla inks out-licensing deal with Stempeutics Research

18 May 2018 Evaluate

Cipla has signed an out-licensing deal with Stempeutics Research, a Biotech firm. The agreement is for stem cell therapy product Stempeucel, indicated for treating critical limb ischemia.

The company will get exclusive marketing rights for five years in India for critical limb ischemia due to atherosclerotic peripheral arterial disease (CLI-PAD) with Stempeutics manufacturing and supplying the product to Cipla.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.


Cipla Share Price

1242.65 -1.25 (-0.10%)
27-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.65
Dr. Reddys Lab 1281.95
Cipla 1242.65
Zydus Lifesciences 896.60
Lupin 2334.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×